ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Change In Receivables : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Change In Receivables?

ImmuneOnco Biopharmaceuticals (Shanghai)'s change in receivables for the quarter that ended in Dec. 2024 was €0.00 Mil. It means ImmuneOnco Biopharmaceuticals (Shanghai)'s Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

ImmuneOnco Biopharmaceuticals (Shanghai)'s change in receivables for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means ImmuneOnco Biopharmaceuticals (Shanghai)'s Accounts Receivable declined by €0.00 Mil from Dec. 2023 to Dec. 2024 .

ImmuneOnco Biopharmaceuticals (Shanghai)'s Accounts Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding for the six months ended in Dec. 2024 was 0.04.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ImmuneOnco Biopharmaceuticals (Shanghai)'s liquidation value for the six months ended in Dec. 2024 was €66.69 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) Change In Receivables Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Change In Receivables Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Change In Receivables

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial			0.01	-	-	-	-

ImmuneOnco Biopharmaceuticals (Shanghai) Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.002	/	9.716	*	91
=	0.04

2. In Ben Graham's calculation of liquidation value, ImmuneOnco Biopharmaceuticals (Shanghai)'s accounts receivable are only considered to be worth 75% of book value:

ImmuneOnco Biopharmaceuticals (Shanghai)'s liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	98.655	-	31.965	+	0.75 * 0.002	+	0.5 * 0
=	66.69

ImmuneOnco Biopharmaceuticals (Shanghai) Change In Receivables Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

01541:Hong Kong

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines